Frequency: Weekly (Goes into printing every Tuesday; On stands …
Launched on 21 December 2000, Chronicle Pharmabiz is the No. 1 Pharma news weekly in the South Asian markets; with a target readership that includes 100% coverage of top and middle …
TopNews - Pharmabiz.com
Dec 24, 2024 · Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic …
Several micro & small pharma units staring at closure as time for ...
3 days ago · With the deadline for the pharma units under Rs. 250 crore turnover to comply with the revised Schedule M manufacturing standards closed by the end of December, 2024, the …
Capricor Therapeutics seeks US FDA approval for deramiocel for …
2 days ago · Capricor Therapeutics, a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced the completion of …
China NMPA accepts and grants priority review status to …
3 days ago · China NMPA accepts and grants priority review status to Hutchmed’s NDA for Orpathys & Tagrisso combination in lung cancer patients with MET amplification after …
Pharma People - Pharmabiz.com
Nov 27, 2024 · Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic …
Editorial - Pharmabiz.com
Nov 6, 2024 · Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic …
US FDA grants priority review status to AstraZeneca & Daiichi …
Oct 3, 2024 · US FDA grants priority review status to AstraZeneca & Daiichi Sankyo’s sBLA for Enhertu for patients with HER2-low or HER2-ultralow metastatic breast cancer who have …
Annovis Bio gets US FDA clearance to begin pivotal phase 3 …
Oct 17, 2024 · Annovis Bio gets US FDA clearance to begin pivotal phase 3 studies of buntanetap, paving the way for NDAs filing: Malvern, Pennsylvania Thursday, October 17, …
US FDA clears Tyra Biosciences’ IND application to proceed with …
Oct 29, 2024 · US FDA clears Tyra Biosciences’ IND application to proceed with phase 2 study of TYRA-300 in paediatric achondroplasia: Carlsbad, California Tuesday, October 29, 2024, …